Camp4 Therapeutics (CAMP) Current Deferred Revenue (2024 - 2026)

Camp4 Therapeutics has reported Current Deferred Revenue for 3 years, with the latest figure at $11.1 million in Q1 2026.

• Quarterly Current Deferred Revenue changed N/A year-over-year to $11.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.1 million (changed N/A YoY) and the FY2025 annual result came in at $9.4 million, up 2338.18% from the prior year.
• Current Deferred Revenue advanced to $11.1 million in Q1 2026 per CAMP's latest filing, from $9.4 million in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $11.1 million in Q1 2026 and troughed at $385000.0 in Q4 2024.
• A 3-year average of $5.5 million and a median of $5.2 million in 2024 frame the typical range for Current Deferred Revenue.
• The widest YoY moves for Current Deferred Revenue: up 2338.18% in 2025, down 2338.18% in 2025.
• Over 3 years, Current Deferred Revenue stood at $385000.0 in 2024, then jumped by 2338.18% to $9.4 million in 2025, then grew by 17.98% to $11.1 million in 2026.
• According to Business Quant data, Current Deferred Revenue over the past three periods registered $11.1 million, $9.4 million, and $385000.0 for Q1 2026, Q4 2025, and Q4 2024 respectively.